Serum levels of hypothalamic-pituitary-testicular axis hormones in men with or without prostate cancer or atypical small acinar proliferation

Clinics

Volumn 66, Issue 2, 2011, Pages 183-187

  Schmitt, Caio da Silva ^a   Rhoden, Ernani Luis ^a   Almeida, Gilberto Laurino ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

Estradiol; Follicle stimulating hormone; Luteinizing hormone; Prolactin; Testosterone

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CASE CONTROL STUDY; CELL PROLIFERATION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CELL PROLIFERATION; ESTRADIOL; FOLLICLE STIMULATING HORMONE; GONADOTROPINS, PITUITARY; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PROLACTIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; STATISTICS, NONPARAMETRIC; TESTOSTERONE;

EID: 79955487599     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000200001     Document Type: Article

References (27)

1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859-864, doi: 10.1016/S0140-6736(03)12713-4.
2. National Institute of Cancer - Health Department/Brazil. Available from: URL: http://www.inca.gov.br/estimativa/2005
3. Reiter RE, deKernion JB. Epidemiology, etiology, and prevention of prostate cancer. In: Walsh PC, editor. Campbell's Urology. 8th ed. Philadelphia: Saunders; 2002. p. 3003.
4. Huggins C, Hodges CV. Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
5. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224, doi: 10.1056/NEJMoa030660.
6. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670-6, doi: 10.1097/01.ju.0000062674.43964.d0.
7. Morgentaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904-1906, doi: 10.1001/jama.276.23.1904.
8. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, et al. Preoperative serum testosterone levels as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52:696-701, doi: 10.1016/j.eururo.2007.03.052.
9. Leite KR, Mitteldorf CA, Camara-Lopes LH. Repeat prostate biopsies following diagnoses of prostate intraepithelial neoplasia and atypical small gland proliferation. Int Braz J Urol. mar-apr 2005;31:131-136, doi: 10.1590/S1677-55382005000200007.
10. Nieschag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, et al. International Society of Andrology (ISA), International Society for the study of the aging male (ISSAM) European Association of Urology (EAU). Investigation, Treatment And Monitoring Of Late-Onset Hypogonadism In Males ISA, ISSAM, And EAU Recommendations. Eur Urol. 2005;48:1-4, doi: 10.1016/j.eururo.2005.04.027.
11. Carter HB, Partin AW. Diagnosis and Staging of Prostate Cancer. In: Walsh PC, editor. Campbell's Urology. 8th ed. Philadelphia: Saunders; 2002. p. 3055.
12. Barret-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population based study of androstenedione, estrogens and prostate cancer. Cancer Res. 1990;50:169.
13. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005;173:1935-1937, doi:10.1097/01.ju.0000158040.33531.e7.
14. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA. 1991;265:618, doi: 10.1001/jama.265.5.618.
15. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88:1118-1126, doi:10.1093/jnci/88.16.1118.
16. Prehn RT. On the prevention and therapy of prostatic cancer by androgen administration. Cancer Res. 1999;59:4161.
17. Endogenous Hormones, Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. JNCI. 2008;100:170-183.
18. San Francisco IF, Regan MM, DeWolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006;175:1341-1345, doi: 10.1016/S0022-5347(05)00680-4.
19. Lane BR, Stephenson AJ, Magi-Gallazzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008;72:1240-1245, doi: 10.1016/j.urology.2008.06.001.
20. Schatzl G, Madersbacher S, Thürridl T, Waldmüller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52-58, doi: 10.1002/pros.1046.
21. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/dL or less. Urology. 2006;68:1263-127, doi: 10.1016/j.urology.2006.08.1058.
22. Curran MJ, Bihrle W, 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology. 1999;53:423-424, doi: 10.1016/S0090-4295(98)00348-3.
23. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, et al. Influence of radical prostatectomy on serum hormone levels. J Urol. 1998;160:449-453, doi: 10.1016/S0022-5347(01)62922-7.
24. Madersbacher S, Schatzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P, et al. Impact of radical prostatectomy and TURP on the hypothalamicpituitary- gonadal hormone axis. Urology. 2002;60:869-874, doi: 10.1016/S0090-4295(02)01893-9.
25. Brausi M, Castagnetti G, Dotti A, De Luca G, Olmi R, Cesinaro AM. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment? J Urol. 2004;172:906-909.
26. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgendependent growth. Eur Urol. 2009;55:310-320, doi: 10.1016/j.eururo.2008.09.024.
27. Porter AT, FACRO, Ben-Josef E. Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol. 2001;6:131-138, doi: 10.1016/S1078-1439(00)00124-1.